恩塞福林：首次批准。
Ensifentrine: First Approval.
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
出版信息
Drugs. 2024 Sep;84(9):1157-1163. doi: 10.1007/s40265-024-02081-w. Epub 2024 Aug 28.
Ensifentrine, an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, is being developed by Verona Pharma plc for the treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD). In June 2024, ensifentrine (OHTUVAYRE™) inhalation suspension was approved for the maintenance treatment of COPD in adult patients in the USA. This article summarizes the milestones in the development of ensifentrine leading to this first approval for the maintenance treatment of COPD.
依诺特林是一种吸入性、选择性磷酸二酯酶（PDE）3 和 PDE4 抑制剂，由 Verona Pharma plc 开发，用于治疗呼吸系统疾病，包括慢性阻塞性肺疾病（COPD）。2024 年 6 月，依诺特林（OHTUVAYRE™）吸入混悬剂在美国获批用于治疗成年 COPD 患者的维持治疗。本文总结了依诺特林的开发里程碑，这些里程碑促成了该药在 COPD 维持治疗方面的首次批准。
Zotero 插件